(Q30224624)

English

A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

1 reference

based on heuristic

inferred from title

Otfried Kistner

13

object named as

Otfried Kistner

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

15

object named as

Thomas R Kreil

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Helga Savidis-Dacho

8

object named as

Helga Savidis-Dacho

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

14

object named as

P Noel Barrett

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

author name string

Walter Wodal

1

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Falko G Falkner

2

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Astrid Kerschbaum

3

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Claudia Gaiswinkler

4

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Richard Fritz

5

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Stefan Kiermayr

6

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Daniel Portsmouth

7

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Sogue Coulibaly

9

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Christina Piskernik

10

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Christine Hohenadl

11

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

M Keith Howard

12

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

language of work or name

0 references

publication date

10 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

4625-4631

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Phylogenetic diversity and genotypical complexity of H9N2 influenza A viruses revealed by genomic sequence analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Human infection with influenza H9N2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Compatibility of H9N2 avian influenza surface genes and 2009 pandemic H1N1 internal genes for transmission in the ferret model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Novel genotypes of H9N2 influenza A viruses isolated from poultry in Pakistan containing NS genes similar to highly pathogenic H7N3 and H5N1 viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A novel genotype H9N2 influenza virus possessing human H5N1 internal genomes has been circulating in poultry in eastern China since 1998.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Immunity to influenza A H9N2 viruses induced by infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A live bivalent influenza vaccine based on a H9N2 virus strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Vaccine preparedness--are we ready for the next influenza pandemic?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Adaptation of pandemic H1N1 influenza viruses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

One-hit models for virus inactivation studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Characterization of a human H9N2 influenza virus isolated in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.102

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.04.102

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30224624&oldid=1550940505"